A290650 Stock Overview
L&C Bio Co., Ltd operates as a research and development company in tissue regeneration medicine. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
L&C BIO Co.,LTD Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩22,550.00 |
| 52 Week High | ₩27,450.00 |
| 52 Week Low | ₩15,000.00 |
| Beta | 0.57 |
| 1 Month Change | 12.75% |
| 3 Month Change | 0% |
| 1 Year Change | 9.47% |
| 3 Year Change | -41.12% |
| 5 Year Change | -9.92% |
| Change since IPO | 151.02% |
Recent News & Updates
L&C BIOLTD's (KOSDAQ:290650) Performance Raises Some Questions
Apr 01
There's No Escaping L&C BIO Co.,LTD's (KOSDAQ:290650) Muted Revenues Despite A 30% Share Price Rise
Dec 14Is L&C BIOLTD (KOSDAQ:290650) A Risky Investment?
Nov 12Recent updates
L&C BIOLTD's (KOSDAQ:290650) Performance Raises Some Questions
Apr 01There's No Escaping L&C BIO Co.,LTD's (KOSDAQ:290650) Muted Revenues Despite A 30% Share Price Rise
Dec 14Is L&C BIOLTD (KOSDAQ:290650) A Risky Investment?
Nov 12Here's Why L&C BIOLTD (KOSDAQ:290650) Has A Meaningful Debt Burden
Aug 06What L&C BIO Co.,LTD's (KOSDAQ:290650) 27% Share Price Gain Is Not Telling You
Jul 05L&C Bio's (KOSDAQ:290650) Performance Raises Some Questions
Mar 27Does L&C Bio (KOSDAQ:290650) Deserve A Spot On Your Watchlist?
Apr 20L&C Bio's (KOSDAQ:290650) Earnings Are Of Questionable Quality
Apr 01Is L&C Bio (KOSDAQ:290650) A Risky Investment?
Mar 02Announcing: L&C Bio (KOSDAQ:290650) Stock Increased An Energizing 163% In The Last Year
Feb 03What Is The Ownership Structure Like For L&C Bio Co., Ltd (KOSDAQ:290650)?
Jan 04Should You Be Excited About L&C Bio Co., Ltd's (KOSDAQ:290650) 16% Return On Equity?
Dec 08Shareholder Returns
| A290650 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 4.4% | 1.0% | -0.2% |
| 1Y | 9.5% | 16.1% | -7.8% |
Return vs Industry: A290650 underperformed the KR Biotechs industry which returned 16.1% over the past year.
Return vs Market: A290650 exceeded the KR Market which returned -7% over the past year.
Price Volatility
| A290650 volatility | |
|---|---|
| A290650 Average Weekly Movement | 6.0% |
| Biotechs Industry Average Movement | 7.8% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in KR Market | 12.4% |
| 10% least volatile stocks in KR Market | 2.9% |
Stable Share Price: A290650 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A290650's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 130 | Chul Lee Whan | www.lncbio.co.kr |
L&C Bio Co., Ltd operates as a research and development company in tissue regeneration medicine. It offers human tissue, medical device, and cosmetics products. The company was founded in 2011 and is headquartered in Seongnam-si, South Korea.
L&C BIO Co.,LTD Fundamentals Summary
| A290650 fundamental statistics | |
|---|---|
| Market cap | ₩511.54b |
| Earnings (TTM) | ₩143.34b |
| Revenue (TTM) | ₩72.09b |
3.6x
P/E Ratio7.1x
P/S RatioIs A290650 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A290650 income statement (TTM) | |
|---|---|
| Revenue | ₩72.09b |
| Cost of Revenue | ₩36.36b |
| Gross Profit | ₩35.73b |
| Other Expenses | -₩107.61b |
| Earnings | ₩143.34b |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 6.32k |
| Gross Margin | 49.56% |
| Net Profit Margin | 198.82% |
| Debt/Equity Ratio | 40.3% |
How did A290650 perform over the long term?
See historical performance and comparisonDividends
0.2%
Current Dividend Yield0.7913%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/06 09:54 |
| End of Day Share Price | 2025/05/02 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
L&C BIO Co.,LTD is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kyung-rae Han | Daishin Securities Co. Ltd. |
| Jongsun Park | Eugene Investment & Securities Co Ltd. |
| Min-jung Kwag | Hyundai Motor Securities Co. Ltd. |